Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05725057Phase 1Completed

Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

Role: lead

NCT05218434Phase 1Completed

A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses

Role: lead

NCT02546635Phase 1Completed

Potential Food Effect And Repeated Dosing of AX-024.HCl In Healthy Subjects

Role: lead

NCT02243683Phase 1Completed

Safety Study of Immune System Modulator for Autoimmune Diseases

Role: lead

All 4 trials loaded